Search company, investor...

Velico Medical

Founded Year



Loan | Alive

Total Raised


Last Raised

$680K | 3 yrs ago

About Velico Medical

Velico Medical, fka ZymeQuest, is engaged in the discovery, development and commercialization of enzymatic blood conversion processing systems for use in blood transfusion medicine. Enzymatic blood conversion aims to enable the precise and permanent conversion of groups A, B and AB red blood cells to ECO (Enzyme Converted O) red blood cells.

Headquarters Location

100 Cummings Ctr # 436H

Beverly, Massachusetts, 01915,

United States


Missing: Velico Medical's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Velico Medical's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Velico Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Velico Medical is included in 1 Expert Collection, including Medical Devices.


Medical Devices

8,562 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

Velico Medical Patents

Velico Medical has filed 1 patent.

The 3 most popular patent topics include:

  • Transfusion medicine
  • Blood
  • Hematology
patents chart

Application Date

Grant Date


Related Topics




Transfusion medicine, Blood, Blood products, Hematology, Coagulopathies


Application Date


Grant Date



Related Topics

Transfusion medicine, Blood, Blood products, Hematology, Coagulopathies



Latest Velico Medical News

Senator Hassan visits Sunrise Labs to discuss R&D Tax Credit

Aug 1, 2019

August 01, 2019 12:08 PM Eastern Daylight Time BEDFORD, N.H.--( BUSINESS WIRE )--Senator Hassan visited Sunrise Labs to discuss her R&D Tax Credit Expansion Act with President, Eric Soederberg. The Senator recognizes the importance of entrepreneurship and innovation and the need for government to encourage and support start-ups. The tax credits will be extended to small businesses with less than $10 million in annual revenue, and will allow startups with little or no profit to take the credit against all their payroll tax. "It gives you a refundable tax credit to help you fund those new ideas that can turn into a profitable business and create jobs and really have the kind of ripple effect that we see here at Sunrise," Hassan said. During her visit, Senator Hassan viewed several of the products Sunrise is working on including the FrontlineODP (On Demand Plasma) system being developed for Velico Medical . Velico’s technology spray-dries blood plasma, which can then be stored with or without refrigeration for long periods and reconstituted with sterile water in 5 minutes at the point of care. Velico Medical is funded by BARDA (the Biomedical Advanced Research and Development Authority), (contract HHSO100201200005C). The availability of plasma at the point of care for bleeding patients is expected to save 10’s of thousands of lives around the world by making plasma readily available for emergency response including mass casualty events, on battlefields, and in other settings where minutes count in saving lives. Many of Sunrise Labs’ clients have taken advantage of the R&D Tax Credits. With the bill Senator Hassan is sponsoring, these startups will be able to use tax credits to offset all payroll taxes. "Now, these startups can run further and longer and thus have a greater chance of success. We work with many of these startups, and I've spoken with several of them that applaud this effort," Soederberg said. Soederberg also had the chance to discuss with the Senator other tax and government issues that challenge businesses. He stressed the need for a stable business environment to encourage investments, and the need for lasting; and therefore, bi-partisan policy to address the big problems, like the Climate Crisis, which pose tremendous risks for businesses.

Velico Medical Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Velico Medical Rank

Velico Medical Frequently Asked Questions (FAQ)

  • When was Velico Medical founded?

    Velico Medical was founded in 1993.

  • Where is Velico Medical's headquarters?

    Velico Medical's headquarters is located at 100 Cummings Ctr # 436H, Beverly.

  • What is Velico Medical's latest funding round?

    Velico Medical's latest funding round is Loan.

  • How much did Velico Medical raise?

    Velico Medical raised a total of $2.13M.

  • Who are the investors of Velico Medical?

    Investors of Velico Medical include Paycheck Protection Program and Novartis Venture Funds.

  • Who are Velico Medical's competitors?

    Competitors of Velico Medical include Mercator MedSystems, Verax Biomedical, Abaxis, ClearCount Medical Solutions, VeraLight and 9 more.

Compare Velico Medical to Competitors

Verax Biomedical

Verax Biomedical is the producer of the Platelet PGD Test, a test for bacterial contamination in platelets granted a Safety Measure claim by the FDA. The test can be used to extend the dating of apheresis platelets in plasma, the most common platelet type transfused in the U.S., from 5 to 7 days. This dating extension offers the opportunity for significant cost savings to the blood banking community while preserving a critical life giving resource.

Pulse Metric

Pulse Metric designs, manufactures and markets products and services that transform a simple blood pressure reading into a powerful functional profile of the patients cardiovascular system, including cardiac output, vessel compliance, vascular resistance and left ventricular contractility. Within a minute of uploading a DynaPulse blood pressure waveform to the DynaPulse Analysis Center website, 17 hemodynamic parameters are calculated, displayed and trended, providing clinicians with numeric values profiling the hearts pumping performance, blood vessel elasticity and vascular resistance, against normative ranges.The company believes the simplicity of its methodology and the significance of the information provided to the physician will improve quality of care while reducing costs. Pulse Metric has been granted nine patents in support of its proprietary technology.


Cardiophotonics develops non invasive blood monitors used to detect cardiac arrhythmia and dehydration


Founded in 1998, Investigen, Inc., is an innovator in DNA testing, developing new processes to shorten testing time and reduce the cost of DNA diagnostic testing and detection of microorganisms and genetically modified organisms (GMOs). Investigen's tests have already demonstrated significant value for food quality assurance, health care, environmental safety, and industry.http://www.investigen.comDidier Perez, Phone: 510-964-9700, Email:


CardioOptics is a developer of Trans-Blood Vision products to provide catheter-based direct visualization through blood using infrared light.


Lifepoint is a medical technology company developing rapid and cost effective, non-invasive, on-site diagnostic products. The Company has developed and will continue to develop patented, proprietary technologies utilizing saliva as a test specimen to provide blood equivalent diagnostic results without the need for blood or urine.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.